Cyclophosphamide

Chronic Progressive Multiple Sclerosis

Bruce CreeSmall moleculePhase 3Active

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 95/ 100

Competitive context

11 Active assets in the Chronic Progressive Multiple Sclerosis cohort.

Asset / Sponsor	Phase	Rating
D-Thioctic Acid Rebecca Spain	Phase 2/3	BB
Rituximab Centre Hospitalier de PAU	Phase 2	B
Masitinib AB Science	Phase 3	B
Cladribine Queen Mary University of London	Phase 2/3	B
Acetylcysteine University of California, San Francisco	Phase 2	B

View all 29 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 4

79 / 100

mycosis fungoidesActive

BBB

Indicative · Phase 4

78 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.